Valeritas Holdings Inc (NASDAQ:VLRX)’s share price fell 3.4% during mid-day trading on Monday . The stock traded as low as $0.30 and last traded at $0.31. 753,928 shares were traded during mid-day trading, a decline of 36% from the average session volume of 1,171,298 shares. The stock had previously closed at $0.33.
Several research firms have recently issued reports on VLRX. Zacks Investment Research lowered Valeritas from a “buy” rating to a “hold” rating in a report on Saturday, March 9th. Oppenheimer reissued a “buy” rating on shares of Valeritas in a report on Monday, January 14th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Valeritas currently has a consensus rating of “Buy” and an average price target of $2.10.
The firm has a market cap of $32.31 million, a price-to-earnings ratio of -0.18 and a beta of 2.04. The company has a quick ratio of 3.98, a current ratio of 4.47 and a debt-to-equity ratio of 2.82.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its holdings in Valeritas by 138.0% during the fourth quarter. Geode Capital Management LLC now owns 186,971 shares of the company’s stock valued at $60,000 after purchasing an additional 108,416 shares during the period. Millennium Management LLC bought a new position in Valeritas during the fourth quarter valued at $165,000. Weiss Multi Strategy Advisers LLC bought a new position in Valeritas during the fourth quarter valued at $41,000. CVI Holdings LLC bought a new position in Valeritas during the fourth quarter valued at $832,000. Finally, Northern Trust Corp lifted its position in shares of Valeritas by 855.4% during the fourth quarter. Northern Trust Corp now owns 185,469 shares of the company’s stock worth $60,000 after acquiring an additional 166,057 shares in the last quarter. 36.46% of the stock is owned by institutional investors and hedge funds.
Valeritas Company Profile (NASDAQ:VLRX)
Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery.
Further Reading: Treasury Bonds
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.